Event Videos

Clinical and prothrombotic profile of hepatic vein outflow tract obstruction.

http://www.ncbi.nlm.nih.gov/pubmed/23884647

Alam S, Khanna R, Mukund A. Clinical and prothrombotic profile of hepatic vein outflow tract obstruction. Indian J Pediatr. 2014 May; 81(5):434-40.

Abstract
OBJECTIVE:

To study the clinical as well as prothrombotic profile and outcome of hepatic venous outflow tract obstruction in children
METHODS:

This is a prospective st.udy of a cohort of hepatic venous outflow tract obstruction (HVOTO) pediatric cases. All children and adolescents presenting with acute or chronic liver disease were screened for HVOTO with ultrasound and Doppler imaging and confirmed by multi-detector computerised tomography (MDCT) with contrast enhancement.
RESULTS:

Published on: 
May-2014
Read more

Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure

http://www.ncbi.nlm.nih.gov/pubmed/24122953

Pugliese R, Fonseca EA, Porta G, Danesi V, Guimaraes T, Porta A, Miura IK, Borges C, Candido H, Benavides M, Feier FH, Godoy A, Cardoso RA, Kondo M, Chapchap P, Neto JS. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology. 2014 May; 59(5):1964-71.
Abstract

Published on: 
Jun-2014
Read more

Giant cell hepatitis with autoimmune haemolytic anaemia in children: proposal for therapeutic approach

http://www.ncbi.nlm.nih.gov/pubmed/24792633

Bakula A, Socha P, Klaudel-Dreszler M, Karolczyk G, Wozniak M, Rutynowska-Pronicka O, Matysiak M. Giant cell hepatitis with autoimmune haemolytic anemia in children: proposal for therapeutic approach. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):669-73.
Abstract
BACKGROUND AND OBJECTIVE:

Giant cell hepatitis (GCH) with autoimmune hemolytic anemia (AIHA) is a rare, progressive disorder in infants and young children. The disease is aggressive and may lead to liver or multi organ failure with fatal prognosis. Therapy with anti-CD20 monoclonal antibody, rituximab (Rtx), proved effective. The primary objective of the study was to evaluate therapy for severe GCH with AIHA.
METHODS:

Published on: 
May-2014
Read more

The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Non Alcoholic Fatty Liver Disease

Naim Alkhouri, Sana Mansoor, Paola Giammaria, Rocio Lopez, Valerio Nobili,
Gastroenterology 2014 May; 146 (7): s 40
http://www.gastrojournal.org/article/S0016-5085%2814%2960040-8/pdf

Background:

Noninvasive hepatic fibrosis scores that predict the presence of advanced fibrosis have been developed and validated in adult patients with NAFLD. There is an urgent need to test and develop similar scores in children with NAFLD. The aim of our study was to assess the utility of commonly used adult fibrosis scores in pediatric NAFLD and to develop a pediatric specific fibrosis score that can predict advanced fibrosis.

Methods:

Published on: 
May-2014
Read more

Lower fructose intake may help protect against development of non-alcoholic Fatty liver in adolescents with obesity.

http://www.ncbi.nlm.nih.gov/pubmed/24345826

Oʼsullivan TA, Oddy WH, Bremner AP, Sherriff JL, Ayonrinde OT, Olynyk JK,

Beilin LJ, Mori TA, Adams LA. Lower fructose intake may help protect against development of non-alcoholic Fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr. 2014 May; 58(5): 624-31.
Abstract
OBJECTIVES:

Although obesity is a major risk factor for non-alcoholic fatty liver (NAFL), not all individuals with obesity develop the condition, suggesting that other factors such as diet may also contribute to NAFL development. We evaluated associations between fructose and total sugar intake and subsequent diagnosis of NAFL in adolescents with obesity and without obesity in a population-based cohort.
METHODS:

Published on: 
May-2014
Read more

The rapid evolution of treatment strategies for hepatitis C

http://www.ncbi.nlm.nih.gov/pubmed/24732866

Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014 May; 109(5):628-35.

Abstract

Hepatitis C virus (HCV) treatment took a major step forward at the end of 2013 with the approvals of the second-generation protease inhibitor Simeprevir (Olysio) and the nucleotide polymerase inhibitor Sofosbuvir (Sovaldi). The interferon-free regimen of Sofosbuvir and ribavirin is now available for genotype 2 and 3 patients. This regimen for 12 weeks is highly effective for genotype 2, whereas genotype 3 has proven to be more challenging and requires 24 weeks of therapy. Genotype 1 patients have reduced exposure to peginterferon-α with a 12-week regimen with sofosbuvir and a 24-week regimen with Simeprevir.

Published on: 
Jun-2014
Read more

Carnitine for prevention of anti-tuberculosis drug-induced hepatotoxicity: a randomized, clinical trial

http://www.ncbi.nlm.nih.gov/pubmed/24325386

Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. J Gastroenterol Hepatol. 2014 May; 29(5):997-1004.

Abstract

BACKGROUND AND AIM:

In the present study, the potential benefits of oral carnitine in preventing antituberculosis drug-induced hepatotoxicity (ATDH) were evaluated.
METHODS:

Published on: 
May-2014
Read more
« first ‹ previous … 143 144 145 146 147 148 149 150 151 … next › last »

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: